The size of Metastasis in the Sentinel Node Is a Predictor of Additional Non-Sentinel Node Positivity


Background: The need for axillary lymph node dissection (ALND) when sentinel lymph nodes (SLN) contain micrometastasis is controversial. The purpose of this study was to determine if the size of tumor in the SLN corresponds with additional positive non-sentinel lymph nodes (non-SLN) in pT1 breast cancer. Methods: This retrospective review of 483 patients with pT1 breast cancer identified 96 patients with tumor positive SLN biopsies between June 1999 and February 2010. The size of SLN metastasis and the number of tumor positive non-SLN were recorded using AJCC criteria. Receiver operating characteristic analysis was used to discriminate the SLN size with the optimal sensitivity, specificity and likelihood ratios (LR) for additional positive non-SLN. Results: Among 96 patients with a tumor positive SLN, 41% (n = 39) had micrometastasis, and 59% (n = 57) had macrometastasis. A positive non-SLN was identified after ALND among 18% (n = 7 of 39) with micrometastasis compared with 39% (n = 22 of 57) with macrometastasis (p = 0.04). The size of the SLN metastasis and presence of additional tumor positive non-SLNs corresponds to a positive likelihood ratio of 1.1 for micrometastasis and 1.6 for macrometastasis (95%CI: 0.56 - 0.74). Conclusions: Increased size of tumor in SLN is associated with greater likelihood of non-SLN positivity and should be considered for more aggressive follow-up and therapy.

Share and Cite:

T. A. Baker, N. Wadhwani, P. Rajan, S. Sarker, G. Aranha, M. Shoup, H. Mattix-Kramer and C. Godellas, "The size of Metastasis in the Sentinel Node Is a Predictor of Additional Non-Sentinel Node Positivity," Journal of Cancer Therapy, Vol. 3 No. 5A, 2012, pp. 712-717. doi: 10.4236/jct.2012.325090.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson, D. C. Bodurka, H. J. Burstein, A. J. Cochran, et al., “American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer,” Journal of Clinical Oncology, Vol. 23, No. 30, 2005, pp. 7703-7720. doi:10.1200/JCO.2005.08.001
[2] A. E. Giuliano, P. S. Dale, R. R. Turner, D. L. Morton, S. W. Evans and D. L. Krasne, “Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy,” Annals of Surgery, Vol. 222, No. 3, 1995, pp. 399-401. doi:10.1097/00000658-199509000-00016
[3] N. Wasif, M. A. Maggard, C. Y. Ko and A. E. Giuliano, “Underuse of Axillary Dissection for the Management of Sentinel Node Micrometastases in Breast Cancer,” Archives of Surgery, Vol. 145, No. 2, 2010, pp. 161-166. doi:10.1001/archsurg.2009.269
[4] D. L. Weaver, “Sentinel Lymph Nodes and Breast Carcinoma: Which Micrometastases Are Clinically Significant?” The American Journal of Surgical Pathology, Vol. 27, No. 6, 2003, pp. 842-845. doi:10.1097/00000478-200306000-00018
[5] N. Wasif, X. Ye and A. E. Giuliano, “Survey of ASCO Members on Management of Sentinel Node Micrometastases in Breast Cancer: Variation in Treatment Recommendations According to Specialty,” Annals of Surgical Oncology, Vol. 16, No. 9, 2009, pp. 2442-2449. doi:10.1245/s10434-009-0549-7
[6] S. D. Edge, D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene, A. Trotti, et al., “AJCC Cancer Staging Handbook, From the AJCC Cancer Staging Manual,” 7th Edition, Springer, New York, 2009.
[7] M. Hulvat, P. Rajan, E. Rajan, S. Sarker, C. Schermer, G. Aranha, et al., “Histopathologic Characteristics of the Primary Tumor in Breast Cancer Patients with Isolated Tumor Cells of the Sentinel Node,” Surgery, Vol. 144, No. 4, 2008, pp. 518-524. doi:10.1016/j.surg.2008.06.006
[8] C. W. Elston, “The Assessment of Histological Differentiation in Breast Cancer,” Australian and New Zealand Journal of Surgery, Vol. 54, No. 1, 1984, pp. 11-15. doi:10.1111/j.1445-2197.1984.tb06677.x
[9] R. R. Turner, K. U. Chu, K. Qi, L. E. Botnick, N M. Hansen, E. C. Glass and A. E. Giuliano, “Pathologic Features Associated with Nonsentinel Lymph Node Metastases in Patients with Metastatic Breast Carcinoma in a Sentinel Lymph Node,” Cancer, Vol. 89, No. 3, 2000, pp. 574-581. doi:10.1002/1097-0142(20000801)89:3<574::AID-CNCR12>3.0.CO;2-Y
[10] M. R Weiser, L. L. Montgomery, L. K. Tan, B. Susnik, D. Y. Leung, P. I. Borgen, et al., “Lymphovascular Invasion Enhances the Prediction of Non-Sentinel Node Metastases in Breast Cancer Patients with Positive Sentinel Nodes,” Annals of Surgical Oncology, Vol. 8, No. 2, 2001, pp. 145-149. doi:10.1007/s10434-001-0145-y
[11] K. U. Chu, R. R. Turner, N. M. Hansen, M. B. Brennan, A. Bilchik and A. E. Giuliano, “Do All Patients with Sentinel Node Metastasis from Breast Carcinoma Need Complete Axillary Node Dissection?” Annals of Surgery, Vol. 229, No. 4, 1999, pp. 536-541. doi:10.1097/00000658-199904000-00013
[12] G. Viale, E. Maiorano, G. Mazzarol, S. Zurrida, V. Galimberti, A. Luini, et al., “Histologic Detection and Clinical Implications of Micrometastases in Axillary Sentinel Lymph Nodes for Patients with Breast Carcinoma,” Cancer, Vol. 92, No. 6, 2001, pp. 1378-1384. doi:10.1002/1097-0142(20010915)92:6<1378::AID-CNCR1460>3.0.CO;2-Y
[13] G. Cserni, D. Gregori, F. Merletti, A. Sapino, M. P. Mano, A. Ponti, et al., “Meta-Analysis of Non-Sentinel Node Metastases Associated with Micrometastatic Sentinel Nodes in Breast Cancer,” British Journal of Surgery, Vol. 91, No. 10, 2004, pp. 1245-1252. doi:10.1002/bjs.4725
[14] A. E. Giuliano, L. Mccall, P. Beitsch, P. Whitworth, P. Blumencranz, A. Leitch, et al., “Locoregional Recurrence after Sentinel Lymph Node Dissection with or Without Axillary Dissection in Patients with Sentinel Lymph Node Metastases,” Annals of Surgery, Vol. 252, No. 3, 2010, pp. 426-433.
[15] C. Aristei, F. Chionne, A. R. Marsella, M. Alessandro, A. Rulli, A. Lemmi, et al., “Evaluation of Level I and II Axillary Nodes Included in the Standard Breast Tangential Fields and Calculation of the Administered Dose, Results of a Prospective Study,” International Journal of Radiation Oncology, Biology and Physics, Vol. 51, No. 1, 2001, pp. 69-73. doi:10.1016/S0360-3016(01)01595-4
[16] P. J. Schlembach, T. A. Buchholz, M. I. Ross, S. M. Kirsner, G. J. Salas, E. A. Strom, et al., “Relationship of Sentinel and Axillary Level I-II Lymph Nodes to Tangential Fields Used in Breast Irradiation,” International Journal of Radiation Oncology, Biology and Physics, Vol. 51, No. 3, 2001, pp. 671-678. doi:10.1016/S0360-3016(01)01684-4
[17] J. S. Wong and J. R. Harris, “Postmastectomy Radiation Therapy,” In, J. R. Harris, M. E. Lippman, M. Morrow and C. K. Osborne, Eds., Diseases of the breast, 3rd Edition, Lippincott Williams & Wilkins, Philadelphia, 2004, pp. 785-799.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.